摘要
血脂异常是动脉粥样硬化性心血管疾病(ASCVD)的核心危险因素。随着生物技术创新,降脂治疗从传统药物(他汀、胆固醇吸收抑制剂)逐步转向靶向疗法[如前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂、血管生成素样蛋白3(ANGPTL3)抑制剂及基因编辑]等前沿技术。本文系统综述降低低密度脂蛋白胆固醇(LDLC)、降低甘油三酯(TG)、升高高密度脂蛋白胆固醇(HDL-C)及降低脂蛋白(a)[Lp(a)]药物的最新研究进展,解析其作用机制、临床证据及未满足的需求,为中国人群血脂管理提供优化依据。
Dyslipidemia is a core risk factor for atherosclerotic cardiovascular diseases(ASCVD).With advances in biotechnology,lipid-lowering strategies have moved from traditional agents(statins and cholesterol-absorption inhibitors)to targeted approaches such as proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors,angiopoietin-like protein 3(ANGPTL3)inhibitors,and emerging gene-editing tools.This review systematically summarizes the latest therapeutic advances that lower low-density lipoprotein cholesterol(LDL-C)and triglycerides(TG),raise high-density lipoprotein cholesterol(HDL-C),or reduce lipoprotein(a)[Lp(a)],and then dissects the mechanisms of action,clinical evidence,and unmet clinical needs to provide optimized strategies for dyslipidemia management in Chinese populations.
作者
卢梦颖
吴娜琼
LU Mengying;WU Naqiong(Cardiometabolic Center,National Center For Cardiovascular Diseases,Fuwai Hospital,CAMS&PUMC,Beijing 100037,China)
出处
《临床药物治疗杂志》
2025年第9期1-7,14,共8页
Clinical Medication Journal
关键词
血脂异常
降脂治疗
研发进展
传统治疗
精准干预
dyslipidemia
lipid-lowering therapy
research progress
traditional treatment
precision intervention
